Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

6.955 -0.175 (-2.45%)
Streaming Delayed Price Updated: 11:17 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic ↗
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function. 
Via Benzinga
News headline image
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Recap: Arcturus Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview: Arcturus Therapeutics ↗
 
Via Benzinga
News headline image
Evaluating NASDAQ:ARCT for Growth Investment Opportunities. ↗
High growth, ROE and beating expectations for NASDAQ:ARCT: growth investors may appreciate this. 
Via Chartmill
News headline image
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Is NASDAQ:ARCT suited for growth investing? ↗
Is ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) suited for growth investing? 
Via Chartmill
News headline image
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
From Achilles Therapeutics PLC
Via GlobeNewswire
News headline image
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
From Arcturus Therapeutics
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential' ↗
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
News headline image
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023 ↗
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
News headline image
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 7, 2024 ↗
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
News headline image
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 ↗
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential. 
Via InvestorPlace
News headline image
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition ↗
We have researched tech stocks for you and have found these three are likely multibaggers in the making. Considering picking them up today. 
Via InvestorPlace
News headline image
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
News headline image
Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT). ↗
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations ↗
Exploring growth characteristics of ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT). 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.